Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional)
ID: 343241Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/343241

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-024.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Catalyst Award for Early-Stage Investigators (ESIs) to support innovative research on HIV comorbidities, coinfections, and complications. This funding opportunity aims to encourage pioneering studies that explore unique biological mechanisms affecting individuals with HIV, with a focus on projects that are distinct from existing research efforts. The award provides up to $350,000 per year for a maximum of five years, with applicants required to commit at least four person-months annually to their research. Interested applicants can find more information and application details at the NIH grants website, with a submission deadline of May 1, 2025.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-024-Full-Announcement.html
    PAR-23-024.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is offering the Catalyst Award for Early-Stage Investigators (ESIs) focused on researching HIV-related comorbidities, coinfections, and complications. This funding opportunity (FOA) aims to support innovative studies that explore unique biological mechanisms leading to health issues in people with HIV. The award encourages proposals distinct from current research endeavors, aimed at transformative solutions. The FOA outlines key dates, application instructions, and eligibility criteria. Each applicant must commit at least four person-months annually to the research, and funding is limited to $350,000 per year over a maximum five-year project period. Applications will be reviewed based on significance, innovation, investigator qualifications, and approach. Projects that are primarily epidemiological or represent a logical expansion of existing research are not eligible. The initiative underscores the NIH's commitment to advancing HIV-related research and fostering new insights into health challenges faced by those living with HIV.
    Similar Opportunities
    Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)" aimed at supporting Early Stage Investigators (ESIs) in conducting innovative preclinical research on HIV/AIDS using NHP models. This grant initiative seeks to empower researchers who are within ten years of their terminal degree and have at least two years of postdoctoral experience, enabling them to explore new research directions that align with the NIH Strategic Plan for HIV and HIV-Related Research for FY 2021-2025. The funding provides a maximum of $400,000 over a two-year period, with applications due by September 7, 2025. Interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities." This initiative aims to support research that investigates the underlying mechanisms contributing to health disparities in HIV and aging, particularly focusing on how multiple comorbidities affect health outcomes and quality of life among individuals from marginalized populations. The program emphasizes a multidisciplinary approach and encourages engagement with community stakeholders to enhance the relevance of the research. Approximately $3 million is available for four awards and $1.5 million for two additional awards for fiscal year 2024, with a project duration of up to five years. Interested applicants can find more information and guidelines at the NIH Grants website and should direct inquiries to grantsinfo@nih.gov. The application deadline is set for January 7, 2026.
    Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at supporting exploratory research into the neuroimmune connections related to HIV and substance use disorders. This initiative seeks to identify and characterize neuroimmune networks and communication pathways, as well as discover novel modulatory tools that can enhance understanding of the regulatory mechanisms contributing to the comorbidity of HIV and substance use disorders. The NIH intends to allocate up to $2 million to fund approximately six awards, with individual budgets not exceeding $275,000 over a two-year period. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research to develop molecules that target HIV proteins or RNA for degradation. The initiative encourages applications focusing on novel therapeutic methods rather than traditional drug discovery approaches, with a total funding amount of $1.2 million anticipated for one to two awards in fiscal year 2025. This opportunity is particularly significant as it seeks to advance research that could overcome existing limitations in HIV treatment methodologies, fostering diverse applicant eligibility from various institutions and organizations, including historically underrepresented groups. Interested applicants must submit their proposals by December 5, 2024, and can find additional information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at exploring innovative HIV cure strategies at the initiation of combination antiretroviral therapy (cART). This initiative seeks to identify and develop interventions that can be applied at the start of cART or following treatment interruptions, with the ultimate goal of achieving sustained treatment-free remission. The funding, available for up to two years with a maximum budget of $275,000, is open to a diverse range of eligible applicants, including higher education institutions, non-profits, and for-profit entities. Interested parties can find more information and application guidelines at the NIH grants website, with a submission deadline set for September 7, 2026.
    Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS)," aimed at supporting multidisciplinary research teams investigating HIV pathogenesis and its associated comorbidities. The initiative seeks to foster collaboration among experts in HIV science, pathobiology, metabolism, and related fields to explore critical health issues such as gastrointestinal health, liver diseases, kidney function, and obesity in the context of HIV. With a total funding allocation of $2 million for 2-3 anticipated awards, applicants can request up to $500,000 per year for a maximum of five years, with proposals due by November 21, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research in integrated care models for HIV/AIDS and substance use disorders. The initiative seeks to improve health outcomes and enhance care coordination for individuals at heightened risk by addressing service delivery gaps through collaborative and evidence-based practices. This grant, with a funding ceiling of $450,000 over three years, is open to a diverse range of eligible applicants, including higher education institutions and community-based organizations, with applications due by March 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-020.html.